Communiqués Finch Therapeutics Group, Inc.

Actions

FNCHQ

US31773D2009

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets 17:24:29 02/09/2026			Varia. 5j.	Varia. 1 janv.
10,35 ^USD	+1,47 %		+1,47 %	-23,26 %

27/04	Acurx Pharmaceuticals, Adiso Therapeutics, Summit Therapeutics, Finch Therapeutics et AstraZeneca annoncent des mises à jour cliniques sur les infections à Clostridium Difficile	CI
26/03	Approbation de la demande de gestion conjointe pour Finch Therapeutics Group, Inc.	CI

Communiqués

21/10/24	Finch Announces Delisting from Nasdaq and SEC Deregistration	AQ
15/08/24	Ferring v Finch: Ripples From The Decision	AQ
09/06/23	FINCH THERAPEUTICS GROUP, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	AQ
09/06/23	Finch Announces Reverse Stock Split of Common Stock	GL
09/06/23	Finch Announces Reverse Stock Split of Common Stock	AQ
30/05/23	FINCH THERAPEUTICS GROUP, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
18/05/23	FINCH THERAPEUTICS GROUP, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
10/05/23	Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates	GL
25/04/23	FINCH THERAPEUTICS GROUP, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
25/04/23	Finch Therapeutics Announces Executive Leadership Transitions	AQ
25/04/23	Finch Therapeutics Announces Executive Leadership Transitions	GL
18/04/23	FINCH THERAPEUTICS GROUP, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
18/04/23	Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement	GL
23/03/23	FINCH THERAPEUTICS GROUP, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ
23/03/23	Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates	AQ
23/03/23	Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates	GL
26/01/23	Finch Therapeutics : Termination of Material Agreement - Form 8-K	PU
26/01/23	FINCH THERAPEUTICS GROUP, INC. : Termination of a Material Definitive Agreement (form 8-K)	AQ
24/01/23	FINCH THERAPEUTICS GROUP, INC. : Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
24/01/23	Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets	AQ
24/01/23	Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets	GL
06/01/23	FINCH THERAPEUTICS GROUP, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
12/12/22	FINCH THERAPEUTICS GROUP, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
14/11/22	FINCH THERAPEUTICS GROUP, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
11/11/22	Finch Therapeutics : Corporate Presentation – November 2022	PU